Bioprinting 3D Human Tissue To Discover And Test New Treatments With Viscient Bio's Keith Murphy

Podcast: Business Of Biotech · Ben Comer

Opublikowano: 2026-10-26

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Keith Murphy, CEO at Viscient Biosciences, unpacks how 3D human tissue models and scaffold-free bioprinting can change the way developers predict drug safety and model disease. Keith traces his professional journey from MIT and Amgen, to founding Organovo and building Viscient and VivoSim (formerly Organovo) into companies that push New Approach Methodologies (NAM) adoption and smarter, more efficient drug development. Keith also shares policy ideas the FDA could use to further incentivize the use of NAMs. <...